Mizoribine as Sole Immunosuppressive Agent in Islet Xenotransplantation Models: A Candidate Immunosuppressant Causing no Adverse Effects on Islets

Mizoribine (MZ) inhibits the differentiation and proliferation of helper T and B cells after antigen recognition by suppressing the purine biosynthesis pathway and nucleic acid synthesis. MZ has been used in kidney transplantation, but distinct data are unavailable for islet transplantation. The pre...

Full description

Bibliographic Details
Main Authors: Michitoshi Yamashita, Takuro Saito, Kazuya Ise, Show Ishii, Yoshihiro Satoh, Takaharu Saito, Ikuro Oshibe, Hirofumi Shimizu, Akira Kenjo, Takashi Kimura, Mitsukazu Gotoh M.D.
Format: Article
Language:English
Published: SAGE Publishing 2012-03-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/096368911X605457
id doaj-377b3d606350442d9a9bc33a90ca2750
record_format Article
spelling doaj-377b3d606350442d9a9bc33a90ca27502020-11-25T03:24:25ZengSAGE PublishingCell Transplantation0963-68971555-38922012-03-012110.3727/096368911X605457Mizoribine as Sole Immunosuppressive Agent in Islet Xenotransplantation Models: A Candidate Immunosuppressant Causing no Adverse Effects on IsletsMichitoshi Yamashita0Takuro Saito1Kazuya Ise2Show Ishii3Yoshihiro Satoh4Takaharu Saito5Ikuro Oshibe6Hirofumi Shimizu7Akira Kenjo8Takashi Kimura9Mitsukazu Gotoh M.D.10Department of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Surgery I, School of Medicine, Fukushima Medical University, Fukushima, JapanMizoribine (MZ) inhibits the differentiation and proliferation of helper T and B cells after antigen recognition by suppressing the purine biosynthesis pathway and nucleic acid synthesis. MZ has been used in kidney transplantation, but distinct data are unavailable for islet transplantation. The present study investigated the efficacy of MZ for islet xenotransplantation. Immunosuppressive effects of MZ were determined by mixed lymphocyte reaction (MLR) assay in vitro. Toxicities for Wistar rat islets were determined by adenosine triphosphate (ATP) contents of islets during 3-day culture and stimulation index in response to glucose after culture. Immunosuppressive effects in vivo were tested in a Wistar-to-B6 islet xenotransplantation model. MZ was administered continuously for 28 days subcutaneously or intramuscularly. MZ inhibited MLR response by approximately 50% at 0.1 μg/ml. ATP contents decreased with MZ >100 μg/ml, while stimulation index was maintained. Continuous infusion of MZ at 10 mg/kg maintained blood concentrations at 0.13–0.19 μg/ml, while intramuscular injection of MZ at 100 mg/kg/day (peak 520 μg/ml at 1 h postinjection) resulted in below measurable levels (<0.03 μg/ml) within 24 h. Graft survival was significantly prolonged following continuous infusion of 10 mg/kg/day compared to controls (31.0 ± 9.5 vs. 13.2 ± 5.2 days; p = 0.002). Furthermore, animals with intramuscular injection at doses of 3.2, 10, or 100 mg/kg/day showed significantly longer graft survival (20.0 ± 7.5, 22.0 ± 7.31, and 24.5 ± 8.1 days, respectively; p < 0.05 each). Histological examination showed significant suppression of lymphocyte infiltration by MZ administration. MZ showed immunosuppressive effects in an experimental islet xenotransplantation model without adverse effects on endocrine function of islet grafts.https://doi.org/10.3727/096368911X605457
collection DOAJ
language English
format Article
sources DOAJ
author Michitoshi Yamashita
Takuro Saito
Kazuya Ise
Show Ishii
Yoshihiro Satoh
Takaharu Saito
Ikuro Oshibe
Hirofumi Shimizu
Akira Kenjo
Takashi Kimura
Mitsukazu Gotoh M.D.
spellingShingle Michitoshi Yamashita
Takuro Saito
Kazuya Ise
Show Ishii
Yoshihiro Satoh
Takaharu Saito
Ikuro Oshibe
Hirofumi Shimizu
Akira Kenjo
Takashi Kimura
Mitsukazu Gotoh M.D.
Mizoribine as Sole Immunosuppressive Agent in Islet Xenotransplantation Models: A Candidate Immunosuppressant Causing no Adverse Effects on Islets
Cell Transplantation
author_facet Michitoshi Yamashita
Takuro Saito
Kazuya Ise
Show Ishii
Yoshihiro Satoh
Takaharu Saito
Ikuro Oshibe
Hirofumi Shimizu
Akira Kenjo
Takashi Kimura
Mitsukazu Gotoh M.D.
author_sort Michitoshi Yamashita
title Mizoribine as Sole Immunosuppressive Agent in Islet Xenotransplantation Models: A Candidate Immunosuppressant Causing no Adverse Effects on Islets
title_short Mizoribine as Sole Immunosuppressive Agent in Islet Xenotransplantation Models: A Candidate Immunosuppressant Causing no Adverse Effects on Islets
title_full Mizoribine as Sole Immunosuppressive Agent in Islet Xenotransplantation Models: A Candidate Immunosuppressant Causing no Adverse Effects on Islets
title_fullStr Mizoribine as Sole Immunosuppressive Agent in Islet Xenotransplantation Models: A Candidate Immunosuppressant Causing no Adverse Effects on Islets
title_full_unstemmed Mizoribine as Sole Immunosuppressive Agent in Islet Xenotransplantation Models: A Candidate Immunosuppressant Causing no Adverse Effects on Islets
title_sort mizoribine as sole immunosuppressive agent in islet xenotransplantation models: a candidate immunosuppressant causing no adverse effects on islets
publisher SAGE Publishing
series Cell Transplantation
issn 0963-6897
1555-3892
publishDate 2012-03-01
description Mizoribine (MZ) inhibits the differentiation and proliferation of helper T and B cells after antigen recognition by suppressing the purine biosynthesis pathway and nucleic acid synthesis. MZ has been used in kidney transplantation, but distinct data are unavailable for islet transplantation. The present study investigated the efficacy of MZ for islet xenotransplantation. Immunosuppressive effects of MZ were determined by mixed lymphocyte reaction (MLR) assay in vitro. Toxicities for Wistar rat islets were determined by adenosine triphosphate (ATP) contents of islets during 3-day culture and stimulation index in response to glucose after culture. Immunosuppressive effects in vivo were tested in a Wistar-to-B6 islet xenotransplantation model. MZ was administered continuously for 28 days subcutaneously or intramuscularly. MZ inhibited MLR response by approximately 50% at 0.1 μg/ml. ATP contents decreased with MZ >100 μg/ml, while stimulation index was maintained. Continuous infusion of MZ at 10 mg/kg maintained blood concentrations at 0.13–0.19 μg/ml, while intramuscular injection of MZ at 100 mg/kg/day (peak 520 μg/ml at 1 h postinjection) resulted in below measurable levels (<0.03 μg/ml) within 24 h. Graft survival was significantly prolonged following continuous infusion of 10 mg/kg/day compared to controls (31.0 ± 9.5 vs. 13.2 ± 5.2 days; p = 0.002). Furthermore, animals with intramuscular injection at doses of 3.2, 10, or 100 mg/kg/day showed significantly longer graft survival (20.0 ± 7.5, 22.0 ± 7.31, and 24.5 ± 8.1 days, respectively; p < 0.05 each). Histological examination showed significant suppression of lymphocyte infiltration by MZ administration. MZ showed immunosuppressive effects in an experimental islet xenotransplantation model without adverse effects on endocrine function of islet grafts.
url https://doi.org/10.3727/096368911X605457
work_keys_str_mv AT michitoshiyamashita mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT takurosaito mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT kazuyaise mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT showishii mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT yoshihirosatoh mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT takaharusaito mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT ikurooshibe mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT hirofumishimizu mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT akirakenjo mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT takashikimura mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
AT mitsukazugotohmd mizoribineassoleimmunosuppressiveagentinisletxenotransplantationmodelsacandidateimmunosuppressantcausingnoadverseeffectsonislets
_version_ 1724601676695863296